SEOM

Somos una sociedad científica, referente en cáncer. Nuestra misión: mejorar la prevención, el diagnóstico, el tratamiento y el seguimiento del cáncer.

[SEOM @_SEOM]

💻 Disponible la #RevistaSEOM digital de junio.
✅️ ¿Qué nos espera en #SEOM26? La Presidencial reflexionará sobre la evolución de la especialidad y los desafíos futuros.
✅️ La supervivencia al cáncer redefine la atención oncológica.
✅️ #OncoNexion26 crece un 30% con el análisis de #ASCO26.
✅️ Así será la gala homenaje a los pacientes con cáncer en #SEOM26.
✅️ Nuevo reportaje de la serie sobre la historia de la Oncología Médica (década 1986-1996) con motivo de #50AñosSEOM.

🔗 https://t.co/pqNPhWvQ3D

[Mario Balsa @MarioBalsaMD]

🚨 Can circulating TKa guide treatment sequencing in BRAFm M1 melanoma? (SECOMBIT, n=81)
https://t.co/13ipb9XvVo

🎯 5y total PFS: 60.8% TKa-low vs 35.0% TKa-high (P=0.004)
💥 5y OS: 70.7% vs 36.9% (P<0.001)
▪️TKa-high patients showed better outcomes with the “sandwich” strategy
📈 TKa increased at PD: potential dynamic disease marker

SECOMBIT could be moving from sequencing by strategy to sequencing by biology…with TKa deciding who really needs the sandwich 🥪

Congrats @AnaArance1 @PAscierto and all the team! 👏🏼

@OncoAlert
@OncoReporte @myESMO @_SEOM
@GrupoMelanoma

[Mario Balsa @MarioBalsaMD]

🚨 The next generation of antibody–drug conjugates (Perspective: @FerMosele @jsoriamd @FAndreMD)
https://t.co/lRvwG68y5N

🎯 Multi-dimensional biomarkers may enable personalized ADC selection
⚡ Diversified constructs & optimized drug-to-antibody ratios could improve efficacy
👀 Faster development frameworks are needed to match the pace of ADC innovation

The next generation of ADCs should carry better ideas 🤔

@OncoAlert
@OncoReporte @myESMO @_SEOM

[SEOM @_SEOM]

🏃‍♂️ El reto solidario de Nicolás de las Heras, dentro de @BiciRacing #RoberContraElCáncer, ha llegado a @A3Noticias.

Los fondos recaudados durante el #CaminoDosFaros se destinarán al Programa de Becas, Proyectos y Premios de SEOM, impulsando la investigación y la formación en Oncología Médica para seguir mejorando la atención a las personas con cáncer.

💚 ¡Gracias, Nico, por convertir cada kilómetro en apoyo a la investigación!

[Mario Balsa @MarioBalsaMD]

🧬 Germline variants in cancer susceptibility genes among patients with mucosal melanoma (n=346; 322-gene panel)
https://t.co/gXZBtsZJUQ

🎯 Germline pathogenic variants in 10.7% (37/346)
▪️ CHEK2, ATM & MITF were most frequent
💥 MITF p.E318K (OR 6.0) and CHEK2 c.1100delC (OR 6.7) enriched vs population controls
👪 ≥2 affected first-degree relatives: 49.0% vs 29.1% (P=0.019)

@OncoAlert
@OncoReporte @myESMO @_SEOM
@GrupoMelanoma

[Mario Balsa @MarioBalsaMD]

🚨 Clinical toxicity of ADCs and ICI–ADC combinations! @NatRevClinOncol
https://t.co/pcOM3r9Bho

▪️ Unified framework separating immune-, payload- and target-related toxicities
🫁 Recognize organ-specific toxicity patterns and manage overlapping ICI–ADC toxicities as immune-mediated until proven otherwise
💥 Practical algorithms for treatment interruption and rechallenge!

The real payload isn’t just the drug, it’s knowing who carries the toxicity 🎯

Congrats to @peters_solange @PGrivasMDPhD @stolaney1 and all the team! 👏🏼 amazing!

@OncoAlert
@OncoReporte @myESMO @_SEOM
@Lung_Cancers @LungCancerRx

[Oriol Mirallas MD @DrMirallas]

🥳 Out in the August issue of @Annals_Oncology

👏🏻 Thanks to all the authors who made it possible
@PaulJiL @Paul_TdL @GiuliaPretelli @ahernandocalvo @MarioBalsaMD @champiatMD

@_SEOM @myESMO @ASCO @OncoAlert

📖 Open Access:
https://t.co/LYpahdWwtw

[Mario Balsa @MarioBalsaMD]

🧬 Immunologic determinants of response to TIL therapy in advanced melanoma! @CellPressNews
https://t.co/KFnPJMja49

🎯 Durable ORR 36% | CR 14% | mPFS 8 mo
▪️ Response linked to CD8+ stem-like & LAG-3+ tumor-reactive TILs
▪️ Tertiary lymphoid structures → ↑ response & PFS
⚠️ Prior ICI exposure → ↓ TIL fitness

@OncoAlert
@OncoReporte @myESMO @_SEOM
@GrupoMelanoma

[Mario Balsa @MarioBalsaMD]

🩸 Longitudinal BRAF ctDNA monitoring after melanoma resection (prospective real-world cohort, n=127; 318 samples)
https://t.co/qxHrNLuhWV

🎯 ctDNA detection tracked disease status: OR 5.90 locoregional | 7.21 metastatic vs NED (both P<0.001)
💥 Detectable ctDNA → HR 17.17 for relapse (P<0.001)
📈 Each ctDNA doubling → HR 1.53 (P<0.001)
⚠️ Strong prognostic signal, but limited sensitivity

The future of melanoma surveillance is not only about what we can see, but what we can already detect🩸

Congrats to @susana_puig and all the authors! 👏🏼

@OncoAlert
@OncoReporte @myESMO @_SEOM @GrupoMelanoma

[El Médico Interactivo @Elmedicoint]

La inmunoterapia se consolida en el tratamiento del cáncer de cabeza y cuello: @_SEOM actualiza los avances terapéuticos con motivo del Día Mundial, que se celebra cada 27 de julio
#DíaMundialDelCáncerDeCabezaYCuello 
#diainternacionaldelcancerdecabezaycuello 
https://t.co/Ol3NkdtEq8

[Mario Balsa @MarioBalsaMD]

🧬 POLR1A: a new driver of melanoma metastasis? (in vivo CRISPR screen, preclinical)
https://t.co/AKGaXN76cw

🔴 High POLR1A expression → worse OS (HR 1.99)
🫁 POLR1A loss impaired migration, invasion & lung colonization
💥 Pol I inhibition with CX-5461 reduced tumor growth and lung metastases

Pol I may be transcribing more than rRNA… 📝

@OncoAlert
@OncoReporte @myESMO @_SEOM @GrupoMelanoma

[SEOM @_SEOM]

‼️ A raíz de la aprobación de la nueva ley antitabaco, @_SEOM recuerda que:

🚭 No fumar continúa siendo la mejor medida preventiva frente al cáncer y otras enfermedades relacionadas con el tabaco. Nunca es tarde para dejar el hábito tabáquico.

🚭 El tabaco es el principal factor de riesgo evitable para el desarrollo de tumores y muertes por cáncer, siendo responsable del 33% de los tumores y de un 22% de las muertes por cáncer.

🚭 Abandonar el hábito tabáquico en cualquier fase del tratamiento oncológico es esencial para mejorar los resultados clínicos.

🚭 Preocupa el uso de vapeadores o cigarrillos electrónicos en jóvenes, en los que representa la puerta de entrada actual al tabaquismo.

https://t.co/lo2hkiH440

[RTVE Noticias @rtvenoticias]

España prohibirá fumar en terrazas, marquesinas, andenes, piscinas o playas.

Además, la nueva ley de tabaco prohíbe expresamente su consumo a los menores. Antes, era solo la venta.

[Paolo Tarantino @PTarantinoMD]

Approximately 30% of HER2+ breast cancers harbor PIK3CA mutations. In this interesting report just published in @ESMO_Open, gedatolisib + trastuzumab yielded an ORR of 43% and PFS 6 months for pretreated, PIK3CAm, HER2+ MBC. Key toxicity: stomatitis. https://t.co/vrsXZA9JgS

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 MSI-H/dMMR mCRC

⚖️ Reconstructed patient-level analysis

🎯 Nivo + ipi vs pembro
📉 PFS HR: 0.64
⚠️ ↑ Grade 3/4 immune-related AEs

🔄 Nivo ≈ pembro
📊 Similar PFS (HR 0.96)

💡 Useful indirect evidence while awaiting head-to-head comparisons.

🔗 https://t.co/ke80EiTbB1
@OncoAlert

[Nieves Martinez Lago MD PhD @DraMartinezLago]

📊 Periop CT + ICI in GEA

🔎 Systematic review, 30 RCTs (N=11,453)
📈 EFS strongly correlated with OS
🎯 R = 0.83
✅ Correlation remained robust across sensitivity analyses
💡 Strong evidence supporting EFS as a surrogate endpoint for OS.

🔗 https://t.co/cCxUIpRexE
@OncoAlert

[Uğur Özkerim @UOzkerim]

Real-world evidence for T-DXd in HER2-mutant NSCLC is encouraging.

In the multinational TRACER/HERTras cohort (n=168):
🔹 ORR: 55%
🔹 mPFS: 7.2 months
🔹 Intracranial ORR: 74%

Patients with active brain metastases were also included, reinforcing the intracranial activity of T-DXd in routine practice.

ILD remains the key toxicity and requires close monitoring.
@OncoAlert @weoncologists @MedwatchKate @ManuelDomine @GlopesMd @_SEOM @IASLC @OncoReporte @JTOonline

[Mario Balsa @MarioBalsaMD]

📝 An old one but a GOOD one!! NK Cell Therapy: A Rising Star in Cancer Treatment (@Cancers_MDPI)
https://t.co/teaX9WcHBz

💥 NK cells offer unique advantages over T cells: MHC-independent cytotoxicity, lower risk of GVHD, and true off-the-shelf potential
▪️ The major challenge remains the immunosuppressive tumor microenvironment, particularly TGF-β–driven NK-cell dysfunction
🎯 Next-generation strategies include CAR-NK cells, IL-15 agonists, and checkpoint blockade targeting NKG2A, TIGIT, and CD47 to restore NK-cell activity.

Perhaps NK cells aren’t just a rising star anymore…they’re ready for a starring role ⭐

#CellTherapy #NKcells
@OncoAlert
@OncoAlert @myESMO @_SEOM

[Mario Balsa @MarioBalsaMD]

🚨 The gut–skin axis in melanoma: from microbial regulatory mechanisms to clinical translation for precision management! Interesting review! @FrontOncology
https://t.co/YhSVp5Flas

💥 How the gut–skin microbiota axis shapes melanoma biology & response to therapy
🎯 Microbiome-driven mechanisms influencing ICI efficacy and toxicity
☝🏼 Microbiota-based biomarkers and therapeutic strategies for precision melanoma care

Could trusting your gut become actual medical advice? 🤔

@OncoAlert @OncoReporte
@GrupoMelanoma @myESMO @_SEOM

[Mario Balsa @MarioBalsaMD]

🚨 This is a good one!! Progress in the development of cytokine armoured CAR T cells: https://t.co/0wxuUPpuqF

🎯 Reviews next-generation armoured CAR T-cell engineering
⚙️ Focuses on cytokine-based strategies to improve persistence and activity in solid tumors
💥 Highlights approaches to enhance efficacy while limiting systemic toxicity

CAR T cells getting the armour they’ve always deserved🛡️

Congrats to @DrMistyJenkins and all the team! 👏🏼

@OncoAlert
@OncoReporte @myESMO @_SEOM